Preview

Медицинский Совет

Расширенный поиск

Место ингибиторов фактора некроза альфа в лечении больных ревматоидным артритом Тактика при различных вариантах течения заболевания

https://doi.org/10.21518/2079-701X-2015-5-106-111

Полный текст:

Аннотация

С увеличением продолжительности использования генно-инженерных биологических препаратов (ГИБП) в реальной клинической практике перед клиницистами возникают новые вопросы: как переходить с одного ГИБП на другой при первичной или вторичной неэффективности, непереносимости предшествующей терапии ГИБП, какова тактика при достижении низкой активности заболевания или ремиссии. В настоящей статье освещаются накопленные за последние годы данные, имеющие значение для практикующих врачей.

Об авторе

Н. В. Чичасова
Институт профессионального образования Первого Московского государственного медицинского университета им. И.М. Сеченова
Россия


Список литературы

1. Smolen JS, Landewe R, BreedveLd FC, et.al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis., 2014, 73: 492-509

2. Насонов Е.Л., Мазуров В.И., Каратеев Д.Е. и соавт. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России» (часть 1). Научно-практ. Ревматология, 2014, 5, 477-494.

3. JR. Curtis, L. Chen, LR. Harrold et al. Physician preference motivates the use anti-tumor necrosis factor therapy independent of clinical disease activity. Arhtr Care Res., 2010, 62: 101-107.

4. Насонов Е.Л. Генно-инженерные биологические препараты в лечении ревматоидного артрита. М.: ИМА-ПРЕСС; 2013. 549.

5. Hyrich KL, Lunt M, Watson KD, et.al. Outcomes after switching from one anti-tumor necrosis factor a agent to a second anti-tumor necrosis factor a agent in patients with rheumatoid arthritis. Results from a large UK National Cohort Study. Arthr Reumat., 2007; 56: 13-20.

6. Virkki LM, Valleala H, Takakubo Y, et.al. Outcomes of switching anti-TNF drugs in rheumatoid arthritis - a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol DOI 10.1007/s10067-011-1779-1. Published online: 07 June 2011.

7. Karlsson JA, Kristensen LE, Kapetanovich MC, et.al. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatol 2008; 47:507-513.

8. Hjardem E, OstergardM, Podenphant J et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis 2007; 66: 1184-1189.

9. Gomez-Reino JJ, Carmona L. and the BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over four-year period. Arthr Res Ther 2006; 8: R29.

10. Solau-Gervais E, Laxenaire N, Cortet B, et.al. Lack of efficacy of the third tumor necrosis factor a after failure of a soluble receptor and a monoclonal antibody. J Rheumatol (Oxf) 2006; 45: 1121-1124.

11. Buch MH, Bingham SJ, Bejarano V, Bryer D, et.al. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum 2007; 57: 448-53

12. Haraoui B, Keystone E, Thorne JC et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004; 31: 2356-2359.

13. lannone F, Trotta F, Monteccuco C et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 2007; 66: 249-225.

14. Cohen G, Courvoisier N, Cohen JD, et.al. The efficiency of switching from infliximab to etan-ercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: 795-800.

15. Lloyd S, Bujkiewicz S, Wailoo A et al. The effectiveness of anti-TNF-a therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. J Rheumatol (Oxf) 2010; 49: 2313-2321.

16. Nam JL, Wintrop KL, van Vollenchoven RF et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010; 69: 976-986.

17. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to Target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-637.

18. Smolen JS, Nash P, Durez P et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomized controlled trial. Lancet 2013; 381: 918-929.

19. Smolen JS et al. The OPTIMA study of metho-trexate and adalimumab: 78-wek outcomes in early rheumatoid arthritis patients based on achieving a low DAS28 target after 26 weeks, EULAR 2011, THUO243.

20. Smolen JS, Emery P, Ferraccioli G et al. Maintenance of remission in rheumatoid arthritis patients with low=moderate disease activity following withdrawal of certolizumab pegol treatment: week 52 results from CERTAIN study. Ann Rheum Dis 2012; 71 (Suppl 3): 361.

21. Emery P, Hammouden M, Fitzgerald O et al. Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrexate: the PRIZE study. Ann Rheum Dis 2013; 72 (Suppl 3): 399.

22. Huizinga TW, Conaghan PG, Martin-Mola E, et.al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis 2015; 74: 35-43.


Просмотров: 83


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)